Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Evidence supporting the addition of specific insulin regimens to oral therapy in patients with type 2 diabetes mellitus is limited. METHODS: In this 3-year open-label, multicenter trial, we evaluated 708 patients who had suboptimal glycated hemoglobin levels while taking metformin and sulfonylurea therapy. Patients were randomly assigned to receive biphasic insulin aspart twice daily, prandial insulin aspart three times daily, or basal insulin detemir once daily (twice if required). Sulfonylurea therapy was replaced by a second type of insulin if hyperglycemia became unacceptable during the first year of the study or subsequently if glycated hemoglobin levels were more than 6.5%. Outcome measures were glycated hemoglobin levels, the proportion of patients with a glycated hemoglobin level of 6.5% or less, the rate of hypoglycemia, and weight gain. RESULTS: Median glycated hemoglobin levels were similar for patients receiving biphasic (7.1%), prandial (6.8%), and basal (6.9%) insulin-based regimens (P=0.28). However, fewer patients had a level of 6.5% or less in the biphasic group (31.9%) than in the prandial group (44.7%, P=0.006) or in the basal group (43.2%, P=0.03), with 67.7%, 73.6%, and 81.6%, respectively, taking a second type of insulin (P=0.002). [corrected] Median rates of hypoglycemia per patient per year were lowest in the basal group (1.7), higher in the biphasic group (3.0), and highest in the prandial group (5.7) (P<0.001 for the overall comparison). The mean weight gain was higher in the prandial group than in either the biphasic group or the basal group. Other adverse event rates were similar in the three groups. CONCLUSIONS: Patients who added a basal or prandial insulin-based regimen to oral therapy had better glycated hemoglobin control than patients who added a biphasic insulin-based regimen. Fewer hypoglycemic episodes and less weight gain occurred in patients adding basal insulin. (Current Controlled Trials number, ISRCTN51125379.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Because many persons do not achieve adequate glycemic control with monotherapy or are at risk for early loss of efficacy with metformin or another monotherapy, combining antihyperglycemic agents is often appropriate.1060”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1060]
Citations
Cites
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Self-citationGlucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Self-citationOhkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Resistance to Insulin Therapy Among Patients and Providers
Peyrot, M., Rubin, R. R., Lauritzen, T., Skovlund, S. E., Snoek, F. J., Matthews, D. R., Landgraf, R., Kleinebreil, L., & Panel, O. B. O. T. I. D. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.11.2673 · Cited by 783
Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
Holman, R. R., Thorne, K. I., Farmer, A. J., Davies, M. J., Keenan, J. F., Paul, S., & Levy, J. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa075392 · Cited by 710
Self-citationHermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Self-citation
Research works printed but not linked: 2
- Horvath K, 2007, Cochrane Database Syst Rev, 2, CD005613
- Siebenhofer A, 2006, Cochrane Database Syst Rev, 2, CD003287
Cited by
Items 301–400 of 666
Kaneto, H., Koshida, R., & Baxter, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14095 · Cited by 12
Ma, Y.-D., Cui, Z., Zhao, D. Y., Wang, Y., Zhang, L., Zhang, X., Guo, W., Yuan, D., Zhang, J., Yue, L.-M., et al. (2020) · Reproductive Sciences · doi:10.1007/s43032-020-00365-6 · Cited by 12
Kanatsuka, A., Kawai, K., Hirao, K., Yokoyama, H., & Kobayashi, M. (2012) · Diabetology International · doi:10.1007/s13340-012-0073-z · Cited by 12
Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE
Mathieu, C., Östenson, C., Matthaei, S., Reaney, M., Krarup, T., Guerci, B., Kiljański, J., Salaun-Martin, C., Sapin, H., & Theodorakis, M. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0037-8 · Cited by 16
“These observations are in line with results of the 4T trial, which indicated that, after 1 year, patients initially treated only with long-acting insulin were more likely to require a change in treatment (additional dose or addition of a second insulin) than patients initially receiving basal-bolus insulin [16] and, a…”
ResultHermanns, N., Lilly, L. C., Mader, J. K., Aberer, F., Ribitsch, A., Kojzar, H., WARNER, J. L., & Pieber, T. R. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815570709 · Cited by 12
Jansen, H. J., Hendriks, J. C. M., de Galan, B. E., PendeRs, G. M., Tack, C. J., & Vervoort, G. (2010) · Endocrine · doi:10.1007/s12020-010-9423-4 · Cited by 13
“This is well in line with other studies which investigate weight gain and insulin therapy [13, 14].”
ResultHsiao, P.-J., Wu, K.-L., Chiu, S.-H., Chan, J., Lin, Y., Wu, C., Wu, C., Kao, S., Fang, T., Lin, S., et al. (2016) · Clinical and Experimental Nephrology · doi:10.1007/s10157-016-1330-4 · Cited by 12
Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia
Boccara, F., Dent, R. E., Ruilope, L. M., & Valensi, P. E. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0586-8 · Cited by 15
“In the first phase of the Treating to Target in Type 2 Diabetes (4-T) study [60], patients with T2DM with suboptimal glycaemic control on metformin and sulfonylurea were randomised to the addition of a biphasic, prandial, or basal analogue insulin.”
BackgroundKoufakis, T., Karras, S. Ν., Zebekakis, P. E., Ajjan, R., & Kotsa, K. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1526278 · Cited by 13
“As shown by the results of The Treating-to-Target in Type 2 Diabetes (4-T) trial [47], basal insulin provides sufficient glycemic control with less weight gain and hypoglycemia rates, compared to prandial and premixed insulins.”
ResultKalain, A., & Omole, O. B. (2020) · African Journal of Primary Health Care & Family Medicine · doi:10.4102/phcfm.v12i1.2163 · Cited by 22
Spollett, G. R. (2012) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2012.00721.x · Cited by 12
“After 3 years of follow-up, however, HbA1c decreased to 7.1%, 6.8%, and 6.9% for the three regimens, respectively, with no significant difference between these results (Holman et al., 2009).”
ResultInfluentialIntensifying insulin treatment: Options, practical issues, and the role of the nurse practitioner
Kruger, D. F. (2012) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2012.00724.x · Cited by 12
“Respective rates of weight gain (5.7 kg; 3.6 kg; 6.4 kg) and hypoglycemia (3.0; 1.7; 5.7 episodes per patient-year) showed the lowest cumulative burdens over 3 years in the basal start insulin group, with the highest cumulative burdens in the prandial start group (Holman et al., 2009).”
BackgroundMethodInfluentialBloomgarden, Z. T. (2011) · Diabetes Care · doi:10.2337/dc10-2235 · Cited by 11
Heller, T., Kloos, C., Kessler, D. S., Muller, N., Thierbach, R., Wolf, G., & Müller, U. (2014) · Diabetic Medicine · doi:10.1111/dme.12616 · Cited by 11
Treatment of Type 2 Diabetes with Biphasic Insulin Analogues
Rizvi, A. A. (2016) · EMJ Diabetes · doi:10.33590/emjdiabet/10310988 · Cited by 12
Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes
Aronoff, S. L. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1285191 · Cited by 11
“With regards to adverse effects, prandial insulin analogs are associated with an increased risk of hypoglycemia [52,53].”
BackgroundAbuelazm, M. T., Ibrahim, A. A. A., Khlidj, Y., Badr, A., Amin, A. M., Elzeftawy, M. A., Gowaily, I., Elsaeidy, A. S., & Abdelazeem, B. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad177 · Cited by 13
“Generally, the risk of hypoglycemia is related to prandial and premixed bolus insulin therapy rather than basal insulin [39, 40].”
BackgroundKim, J., Ahn, J., Kim, S., Lee, D., Kim, H., Shon, H., Jeon, H.-J., Kim, T., Cho, Y., Kim, J., et al. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12261 · Cited by 12
Detemir as a once-daily basal insulin in type 2 diabetes
Nelson (2011) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s19539 · Cited by 11
Anyanwagu, U., Mamza, J., Donnelly, R., & IDRIS, I. R. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2945 · Cited by 11
Pollock, R. F., Norrbacka, K., Cameron, C. G., Mancillas‐Adame, L. G., & Jeddi, M. (2019) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2018-0073 · Cited by 12
Bolli, G. B., Lucidi, P., Porcellati, F., & Fanelli, C. G. (2011) · Diabetes Care · doi:10.2337/dc11-s224 · Cited by 12
“However, the hypoglycemia risk is associated primarily with prandial and premixed, not basal, insulin treatment (30,31).”
BackgroundInfluentialThe future of insulin therapy for patients with type 2 diabetes mellitus.
Tibaldi, J. M. (2013) · PubMed · Cited by 14
Lixisenatide – A New Glucagon-like Peptide 1 Receptor Agonist in the Treatment of Type 2 Diabetes
Vidal, J. (2010) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2013.09.02.76 · Cited by 15
“However, this approach has limitations, including greater complexity for patients, increased risk of hypoglycaemia and likelihood of leading to weight gain.(32) Thus, it could be considered that adequate control of ppg remains an unmet clinical need in diabetes therapy.”
Insulin initiation in Type 2 diabetes: the implications of the 4‐T study
Holt, R. I. G. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02910.x · Cited by 11
Kawaguchi, Y., Sawa, J., Hamai, C., Nishimura, Y., & Kumeda, Y. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13038 · Cited by 10
An overview of insulin therapy for the non‐specialist
Home, P. D. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16280 · Cited by 13
“37,38 This issue, and the matching of insulin doses to meal size and physical activity, results in much more complex self-management needs than for basal insulin alone, and that in turn requires a higher level of patient education and support.”
Ko, M. S. M., Lee, W. K., Ang, L. C., Goh, S., Bee, Y. M., & Teh, M. M. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109236 · Cited by 11
Continuous Subcutaneous Insulin Infusions: Closing the Loop
Díaz-Balzac, C. A., Pillinger, D., & Wittlin, S. D. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac746 · Cited by 11
Yki‐Järvinen, H., & Kotronen, A. (2013) · Diabetes Care · doi:10.2337/dcs13-2026 · Cited by 11
Hirsch, I. B., Buse, J. B., Leahy, J. L., McGill, J. B., Peters, A. L., Rodbard, H. W., Rubin, R. R., Skyler, J. S., Verderese, C. A., & Riddle, M. C. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12136 · Cited by 11
Optimizing management of glycaemia
Chatterjee, S., Khunti, K., & Davies, M. J. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.06.002 · Cited by 15
Self-citationHong, T., Lü, J., Zhang, P., Zhang, Z., Xu, Q., Li, Y., Cui, N., Grijalva, A., Murray, E. M., del Aguila, M. A., et al. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0606-6 · Cited by 11
Wahlqvist, P., WARNER, J. L., & Morlock, R. (2018) · Journal of health economics and outcomes research · doi:10.36469/9789 · Cited by 12
Fulcher, G. R., Jarlov, H., Piltoft, J. S., Singh, K. P., Liu, L., Mohamed, M., Nicodemus, N. A., Aljaser, S., & Kok, A. (2021) · Endocrine · doi:10.1007/s12020-021-02887-8 · Cited by 11
Evans, M., Chubb, B., Malkin, S. J. P., Berry, S., Lawson, J., & Hunt, B. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14892 · Cited by 10
Choi, S., Lee, J., Lee, J. H., Kim, S., Han, S., Kim, I., & Noh, Y. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2416 · Cited by 11
“therapy in Western patients with type 2 diabetes [20,21] or short-term CSII or multiple daily injection therapy in patients with newly diagnosed type 2 diabetes [9–12]”
BackgroundHall, G. C., McMahon, A. D., Carroll, D., & Home, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049908 · Cited by 10
“HbA1c levels later converged in the 4-T study after usual addition of other insulins, [15] and in the Treat to Target study more glargine users eventually achieved a target of HbA1c #7.”
BackgroundInsulin therapy for type 2 diabetes
Meneghini, L. (2012) · Endocrine · doi:10.1007/s12020-012-9817-6 · Cited by 14
“Initiating and optimizing basal insulin therapy results in the improvement in fasting plasma glucose and A1C, while minimizing the known side effects of insulin, namely hypoglycemia and weight gain; side effects that are more prevalent as rapid-acting insulin formulations are introduced into the treatment plan [3, 26].”
Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2
Torre, E. L. M., Tejedor, F. J. L., Menéndez, S. A., Núñez-Cortés, J. M., Garcia, A. A., Puig‐Domingo, M., Soláns, J. R. G., Guisasola, F. Á., Alegría, J. G., Bravo, J. J. M., et al. (2011) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2010.07.005 · Cited by 16
Inzucchi, S. E., & Sherwin, R. S. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00237-2 · Cited by 10
Herrmann, K., Shan, K., Brunell, S. C., & Chen, S. (2014) · Endocrine Practice · doi:10.4158/ep13477.or · Cited by 9
Khunti, K., Damcı, T., Husemoen, L. L. N., Babu, V., & Liebl, A. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.11.028 · Cited by 10
Shanmugasundar, G., Bhansali, A. K., Walia, R., Dutta, P. R., & Upreti, V. (2012) · The Indian Journal of Medical Research · doi:10.4103/0971-5916.93428 · Cited by 9
Diversity in diabetes: the role of insulin aspart
Heller, S. R., McCance, D. R., Moghissi, E. S., Nazeri, A., & Kordonouri, O. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1240 · Cited by 10
“A recent study has also provided long-term data on the efficacy and safety of insulin aspart as part of a basal–bolus regimen with insulin detemir in patients with type 2 diabetes [52,53].”
BackgroundBashan, E., & Hodish, I. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.03.012 · Cited by 9
“, 2003); - Insulin-treated patients managed in extended clinical trials can be highly successful in achieving the A1C goal for years (2002; Holman et al., 2009); - Regimens using fixed doses of basal or premixed insulins can be highly effective (Buse, Wolffenbuttel et al.”
BackgroundGlycaemic management of type 2 diabetes
Kela, R., Srinivasan, B., & Davies, M. J. (2010) · Medicine · doi:10.1016/j.mpmed.2010.08.006 · Cited by 11
Self-citationRecommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes
Torre, E. L. M., Tejedor, F. J. L., Menéndez, S. A., Núñez-Cortés, J. M., Garcia, A. A., Puig‐Domingo, M., Soláns, J. R. G., Guisasola, F. Á., Alegría, J. G., Bravo, J. J. M., et al. (2011) · Endocrinología y Nutrición (English Edition) · doi:10.1016/s2173-5093(11)70022-8 · Cited by 11
Yadgar‐Yalda, R., Colman, P. G., Fourlanos, S., & Wentworth, J. M. (2016) · Internal Medicine Journal · doi:10.1111/imj.13122 · Cited by 10
Lee, B., Kim, J. H., Ko, S., Hur, K. Y., Kim, N. H., Rhee, S. Y., Kim, H. J., Moon, M. K., Park, S.-O., & Choi, K. M. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2017.314 · Cited by 9
“These recommendations were based on the non-inferior results of basal insulin + single injection of either rapid-acting insulin or GLP-1RA relative to twice daily premixed insulin [12,13,32-35].”
BackgroundInsulin therapy for type 2 diabetes – are we there yet? The d-Nav® story
Hodish, I. (2018) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-018-0056-5 · Cited by 10
“Initially, many patients can do well with simple regimens such as long-acting insulin only, yet over a period of a few years most require some level of fast acting insulin coverage to maintain appropriate glycemia [6].”
BackgroundInfluentialDempsey, M. A., Mocarski, M., Langer, J., & Hunt, B. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1513406 · Cited by 10
Füchtenbusch, M., Aberle, J., Heitmann, E., Nicolay, C., & Jung, H. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13658 · Cited by 11
“Among insulin regimens, however, this treatment has the highest risk of hypoglycaemia and weight gain.(20,21) Patients may be reluctant to accept such a treatment scenario as they are concerned about reduced flexibility in lifestyle, as well as weight gain and the risk of hypoglycaemia.”
BackgroundAn update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus
Novodvorský, P., & Haluzík, M. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1978974 · Cited by 13
Emerging role of insulin with incretin therapies for management of type 2 diabetes
Ahluwalia, R., & Vora, J. (2011) · Diabetes Therapy · doi:10.1007/s13300-011-0005-0 · Cited by 12
What Options Are Available When Considering Starting Insulin: Premix or Basal?
Lavernia, F. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0248 · Cited by 10
“The authors concluded that, on balance, patients who added a basal or prandial insulin-based regimen to oral therapy had better A1C control than patients who added a premix insulin-based regimen.(38) Because the basal insulin regimen was also associated with fewer hypoglycemic episodes and less weight gain, this treat…”
InfluentialSaid, E., Farid, S. F., Sabry, N. A., & Fawzi, M. (2013) · Pharmacology & Pharmacy · doi:10.4236/pp.2013.47080 · Cited by 9
“[26].”
Current insulin analogues in the treatment of diabetes: emphasis on type 2 diabetes
Esposito, K., & Giugliano, D. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.648181 · Cited by 9
Martínez, J. J. G. (2011) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2011.09.007 · Cited by 12
Ilany, J., Bhandari, H., Nabriski, D., Toledano, Y., Konvalina, N., & Cohen, O. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13214 · Cited by 7
“goal of HbA1c < 7%.(5,6) For these patients, there has been growing acceptance of a strategy that progressively adds “bolus” rapid insulin”
BackgroundSex Differences And Relationship Between Blood Pressure And Age Among The Ibos Of Nigeria
Warren, M. L. (2009) · The Internet Journal of Biological Anthropology · doi:10.5580/2cc · Cited by 9
Weight effects of antidiabetic agents
Higbea, A. M., Duval, C., Chastain, L. M., & Chae, J. (2017) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2017.1395694 · Cited by 11
Strategies for implementing effective mealtime insulin therapy in type 2 diabetes
Peyrot, M. F., Bailey, T. S., Childs, B. P., & Reach, G. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1440200 · Cited by 10
The use of insulin in elderly patients with type 2 diabetes mellitus
Mannucci, E., Cremasco, F., Romoli, E., & Rossi, A. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.633512 · Cited by 9
“In fact, randomized trials comparing schemes of insulin treatment are very few [42,43].”
BackgroundWang, W., Yan, X., Cheng, Z., Zhang, Q., Wang, R., Deng, Y., Ma, J., & Zhu, D. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15263 · Cited by 8
Insulin degludec is a new ultra-long-acting insulin analogue
Dedov, I. I., & Shestakova, M. V. (2014) · Diabetes Mellitus · doi:10.14341/dm2014291-104 · Cited by 8
Methods to enhance delivery of prandial insulin and basal‐prandial insulin
Garber, A. J. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12067 · Cited by 8
“Patients requiring two types of insulin at 3 years [2].”
BackgroundInfluentialDamcı, T., Emral, R., Svendsen, A. L., Balkir, T., & Vora, J. P. (2014) · BMC Endocrine Disorders · doi:10.1186/1472-6823-14-61 · Cited by 11
Insulin analogs for the management of type 2 diabetes
Taylor, J. R., & Campbell, K. M. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp110381 · Cited by 8
Wilding, J. P. H., & Bain, S. C. (2015) · Diabetic Medicine · doi:10.1111/dme.13021 · Cited by 8
Jude, E. B., Nixon, M., O’Leary, C., Myland, M., Gooch, N., Shaunik, A., & Lew, E. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0667-6 · Cited by 10
González, C., Fagour, C., Maury, E., Gatta‐Cherifi, B., Salandini, S., Pierreisnard, A., Masquefa-Giraud, P., Gin, H., & Rigalleau, V. (2014) · Diabetes & Metabolism · doi:10.1016/j.diabet.2014.02.001 · Cited by 8
Blackberry, I., Furler, J., Ginnivan, L., Derraz, H., Jenkins, A. J., Cohen, N. D., Best, J. D., Young, D. Y. L., Liew, D., Ward, G. M., et al. (2014) · BMC Family Practice · doi:10.1186/1471-2296-15-82 · Cited by 8
“Once insulin has been initiated, the ongoing monitoring and review of glucose levels by the patient and health professional is important for patient safety and for intensification of insulin therapy [13] as this provides insight into recurring patterns of glycemia, the impact of diet and behavior upon glycemia and the…”
BackgroundFloch, J. P. L. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmsott.s7315 · Cited by 14
Sakharova, O. V., Lleva, R. R., Dziura, J. D., Spollett, G. R., Howell, S. K., Beisswenger, P. J., & Inzucchi, S. E. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.03.027 · Cited by 8
“Results of trials comparing the overall effectiveness of various insulin regimens to control glucose have differed (Bretzel, Eckhard, Landgraf, Owens, & Linn, 2009; Fritsche, Larbig, Owens, & Haring, 2010; Holman et al., 2009).”
BackgroundCombination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin
Ahmann, A. (2015) · Drugs in Context · doi:10.7573/dic.212288 · Cited by 8
“However, basal-bolus treatment may be associated with reduced adherence due to increased number of injections [8], and is associated with weight gain and increased risk of hypoglycemia [13].”
Imam, S. K. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-800093-9.00003-x · Cited by 8
Thomsen, R. W., Baggesen, L. M., Søgaard, M., Pedersen, L. H., Nørrelund, H., Buhl, E. S., Haase, C., & Johnsen, S. P. (2016) · Diabetic Medicine · doi:10.1111/dme.13168 · Cited by 8
Chen, Z., Bi, H., Wang, J., Ma, R., Wang, Y., Dong, B., Lu, C., Wang, J., Li, Y., Zheng, J., et al. (2025) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2025.124069 · Cited by 10
Guo, L., Dong, X., Ma, J., Liu, M., Lu, Y., Wang, H., Li, Q., Li, L., Deng, Y., & Xu, J. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00248-7 · Cited by 11
Kanatsuka, A., Sato, Y., Kawai, K., Hirao, K., Kobayashi, M., & Kashiwagi, A. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12194 · Cited by 7
Raval, A. D., Nguyen, M. H., Zhou, S., Grabner, M., Barron, J. O., & Quimbo, R. A. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.25.10.1111 · Cited by 11
Margaritidis, C., Karlafti, E., Kotzakioulafi, E., Kantartzis, K., Τζιόμαλος, Κ., Kaiafa, G. D., Savopoulos, C. G., & Didangelos, T. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10091982 · Cited by 9
“The 4-T study demonstrated that a single injection of basal insulin is as effective as a prandial and a premixed insulin in reducing HbA1c, but with less hypoglycemia and weight gain [3].”
BackgroundInsulintherapie bei Diabetes mellitus
Lechleitner, M., Roden, M., Weitgasser, R., Ludvik, B. H., Fasching, P., Hoppichler, F., Kautzky‐Willer, A., Schernthaner, G., Prager, R., & Wascher, T. C. (2012) · Wiener klinische Wochenschrift · doi:10.1007/s00508-012-0266-2 · Cited by 7
Bi, Y., Li, X., Yang, D., Hao, Y., Liang, H., Zhu, D., & Weng, J. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00187.x · Cited by 8
A New Look at Established Therapies
Gavin, J. R., Peragallo‐Dittko, V., & Rodgers, P. T. (2010) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721710369637 · Cited by 7
Kumar, A. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.179993 · Cited by 7
“Holman et al.[36]‡ 3‐year, O‐L, R, M; BIAsp 30 bid (n=235), prandial IAsp tid (n=239), basal IDet od or bid (n=234) Uncontrolled on OADs (n=708) No significant difference between treatments (−1.”
BackgroundInfluentialMiikkulainen, K., Caruso, A., Mast, O., Zhang, R., & Borisenko, O. (2016) · BMC Endocrine Disorders · doi:10.1186/s12902-016-0102-1 · Cited by 10
“NCT00184600 N Holman [18] 2009 RCT 708 61.”
Matsuba, I., Sawa, T., Kawata, T., Kanamori, A., Jiang, D., Machimura, H., Takeda, H., Han, J. H., Wang, K., Tanaka, K., et al. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0178-7 · Cited by 9
“Based on clinical trial results, insulin is the most effective glucose-lowering therapy and can improve quality of life by preventing hyperglycemia and reducing diabetic complications [4, 5].”
BackgroundRecomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2
Torre, E. L. M., Tejedor, F. J. L., Menéndez, S. A., Núñez-Cortés, J. M., Garcia, A. A., Puig‐Domingo, M., Soláns, J. R. G., Guisasola, F. Á., Alegría, J. G., Bravo, J. J. M., et al. (2011) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2011.01.007 · Cited by 8
Ray, K. K., Kendall, D. M., Zhao, Z., Peng, X., Caballero, A. E., Polonsky, W. H., Nordstrom, B. L., Fan, L., Curtis, B. H., & Davies, M. J. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13622 · Cited by 8
“Years physician has treated patients with diabetes, median (IQR) 14 (10-21) 13 (11-20) 12 (9-15) 20 (12-25)**”
Self-citationRados, D. R. V., Viecceli, C., Pinto, L. C. F., Gerchman, F., Leitão, C. B., & Gross, J. L. (2020) · Scientific Reports · doi:10.1038/s41598-020-69738-w · Cited by 7
Diabetes in Long-Term Care Facilities
Singhal, A., Segal, A. R., & Munshi, M. N. (2014) · Current Diabetes Reports · doi:10.1007/s11892-013-0464-y · Cited by 7
Reznik, Y., Habteab, A., Castañeda, J., Shin, J., & Joubert, M. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13398 · Cited by 8
“The standard of care for MDI therapy combines a long-acting and a rapid-acting insulin analog,(1) but even this insulin regimen may not allow all patients to reach the glucose target.(3,6,7) Understanding the factors that contribute to hyperglycaemia in situations of MDI failure may help to determine the most appropri…”
BackgroundBuchholz, C., Kahle, M., Meier, J. J., & Nauck, M. A. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0972-9700 · Cited by 8
Kanatsuka, A., Kawai, K., Hirao, K., Yokoyama, H., & Kobayashi, M. (2012) · Cited by 7
Gonzalez-Flo, E., Kheirabadi, E., Rodríguez‐Caso, C., & Macía, J. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1149698 · Cited by 6
“Although insulin is a highly effective therapy for diabetes, the use of exogenous insulin is been associated with a number of side effects, including weight gain, a worsening of diabetic retinopathy, changes in the refractive properties of the lens, dizziness, and difficulty breathing (Lebovitz, 2011) (Holman et al.,…”
BackgroundTriple terapia en diabetes tipo 2: revisión sistemática de la evidencia disponible
Millán, C. O., Pérez, J. A. F., García-Mayor, R. V., & Torre, E. L. M. (2010) · Avances en Diabetología · doi:10.1016/s1134-3230(10)64016-1 · Cited by 6
Monnier, L. (2017) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(17)30031-7 · Cited by 6
Black, J. E., Harris, S. B., Ryan, B. L., Zou, G., & Ratzki‐Leewing, A. A. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01423-3 · Cited by 7
“Real-world safety data favoring secondgeneration basal insulins could inspire their increased use—in the US, despite high dispensation rates for basal insulins in general [23, 24], prescribing of either insulin degludec and glargine U-300 remains relatively low [25].”
Metadata
- Authors
- Holman, R. R., Farmer, A. J., Davies, M. J., Levy, J. C., Darbyshire, J. L., Keenan, J. F., & Paul, S. K.
- Affiliations
- University of Oxford (GB)
- University of Leicester (GB)
- Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-10-29
- Volume
- 361
- Issue
- 18
- Pages
- 1736-1747
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2057595002
- Cited by
- 667
- References
- 26
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 10 · 2023: 12 · 2022: 18 · 2021: 22 · 2020: 21 · 2019: 27 · 2018: 33 · 2017: 45 · 2016: 46 · 2015: 49 · 2014: 68 · 2013: 60 · 2012: 78
- FWCI
- 57.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Leicester Research Archive (University of Leicester) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, insulin therapy, biphasic insulin aspart, insulin detemir, basal insulin, HbA1c, glycemic control, hypoglycemia, weight gain, metformin, sulfonylureas
- MeSH terms
- Administration, Oral, Diabetes Mellitus, Type 2, Drug Administration Schedule, Drug Therapy, Combination, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Metformin, Middle Aged, Sulfonylurea Compounds, Weight Gain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.